

*Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics*

## Cellanyx Diagnostics News – Announcement of New Board Member Dr. David Albala

July 1, 2013

Cellanyx is pleased to announce the appointment of Dr. David Albala to its Senior Advisory Board. Senior Advisory Board (SAB) members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, and advise on clinical, strategic, and technical developments. Importantly, Cellanyx's SAB members share business, scientific, process and regulatory practices that keep the company operating according to the highest standards.

Dr. David Albala comes to Cellanyx with tremendous science and leadership talent. Dr. Albala serves as Chief of Urology at Crouse Hospital in Syracuse, New York and Medical Director for Associated Medical Professionals. Dr. Albala has over 20 years of laparoscopic and robotic urological surgery expertise recognized worldwide. During his distinguished medical career, he was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He also practiced at Loyola University Medical Center in Chicago where he became Professor in Urology and Radiology. Later on, he became a tenured Professor at Duke University Medical Center in North Carolina where he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. Dr. Albala's additional clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH) and the use of fibrin sealants in surgery. He serves as a Member of Advisory Board of TransEnterix, Inc. He serves on the editorial board for the Journal of Robotic Surgery, Journal of Endourology, Current Opinions in Urology and Urology Index and Reviews. He is also a reviewer for eight surgical journals. Dr. Albala received his medical school training at Michigan State University and completed his surgical residency at the Dartmouth-Hitchcock Medical Center.

Dr. Albala is eager to gain a more in-depth understanding of the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that he will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

---

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.  
One Marina Park Drive,  
14th floor  
Boston, MA, 02210  
Main: 571.212.9991  
Email: [info@cellanyx.com](mailto:info@cellanyx.com)